Separately, Zacks Investment Research raised shares of NOVOZYMES A/S/S from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $54.00.
NVZMY stock opened at $41.15 on Monday. The stock has a market capitalization of $12.24 billion, a PE ratio of 23.51, a price-to-earnings-growth ratio of 1.93 and a beta of 0.70. The company’s 50-day moving average is $45.54 and its 200-day moving average is $46.23. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.22 and a quick ratio of 0.71. NOVOZYMES A/S/S has a 1 year low of $40.38 and a 1 year high of $55.84.
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.